Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.
Phase of Trial: Phase II/III
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EXEPUMP
- 07 Jun 2017 Biomarkers information updated
- 22 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 09 Feb 2016 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.